Nothing Special   »   [go: up one dir, main page]

MX2024011183A - Tratamientos conjuntos para el cancer de mama. - Google Patents

Tratamientos conjuntos para el cancer de mama.

Info

Publication number
MX2024011183A
MX2024011183A MX2024011183A MX2024011183A MX2024011183A MX 2024011183 A MX2024011183 A MX 2024011183A MX 2024011183 A MX2024011183 A MX 2024011183A MX 2024011183 A MX2024011183 A MX 2024011183A MX 2024011183 A MX2024011183 A MX 2024011183A
Authority
MX
Mexico
Prior art keywords
breast cancer
combination therapies
trastuzumab
pertuzumab
positive
Prior art date
Application number
MX2024011183A
Other languages
English (en)
Inventor
Jing Zhu
Eleonora Restuccia
Daniel Eiger
Marc Antoine Hafner
Sarah Louise Heeson
Ciara Metcalfe
Mina Nikanjam
Raf Poppe
Mahesh Ratanlal Shivhare
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2024011183A publication Critical patent/MX2024011183A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente solicitud divulga combinaciones para tratar pacientes con cáncer de mama positivo para receptores de estrógeno y positivo para HER2. Las combinaciones comprenden pertuzumab y trastuzumab (por ejemplo, una combinación de dosis fija de pertuzumab y trastuzumab, PH FDC) más giredestrant. En una forma de realización, la combinación incluye además un inhibidor de CDK4/6, tal como abemaciclib o palbociclib.
MX2024011183A 2022-03-14 2023-03-10 Tratamientos conjuntos para el cancer de mama. MX2024011183A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263269326P 2022-03-14 2022-03-14
PCT/US2023/064143 WO2023178019A1 (en) 2022-03-14 2023-03-10 Combination therapies for breast cancer

Publications (1)

Publication Number Publication Date
MX2024011183A true MX2024011183A (es) 2024-09-18

Family

ID=85937455

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011183A MX2024011183A (es) 2022-03-14 2023-03-10 Tratamientos conjuntos para el cancer de mama.

Country Status (6)

Country Link
CN (1) CN118843461A (es)
AU (1) AU2023234511A1 (es)
IL (1) IL315153A (es)
MX (1) MX2024011183A (es)
TW (1) TW202400230A (es)
WO (1) WO2023178019A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042133A1 (en) 1999-01-15 2000-07-20 Infineum International Ltd Improved fuel compositions
MA47313B1 (fr) 2017-01-17 2020-12-31 Hoffmann La Roche Formulations sous-cutanées d'anticorps her2
KR20230009390A (ko) * 2020-05-12 2023-01-17 제넨테크, 인크. Gdc-9545 및 cdk4/6 억제제를 포함하는 병용 요법을 사용한 유방암 치료
KR20230030621A (ko) 2020-06-29 2023-03-06 제넨테크, 인크. 퍼투주맙 + 트라스투주맙 고정 용량 조합
KR20230037560A (ko) 2020-07-14 2023-03-16 에프. 호프만-라 로슈 아게 고정 용량 조합에 대한 분석

Also Published As

Publication number Publication date
AU2023234511A1 (en) 2024-09-12
WO2023178019A1 (en) 2023-09-21
IL315153A (en) 2024-10-01
CN118843461A (zh) 2024-10-25
TW202400230A (zh) 2024-01-01

Similar Documents

Publication Publication Date Title
MX2024011183A (es) Tratamientos conjuntos para el cancer de mama.
Tupchong et al. Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: long-term follow-up of RTOG study 73-03
Poulsen et al. Does chemotherapy improve survival in high-risk stage I and II Merkel cell carcinoma of the skin?
MX2022013163A (es) Anticuerpo contra nectin-4 y aplicacion del mismo.
Ozyigit et al. Current role of modern radiotherapy techniques in the management of breast cancer
Chen et al. Intensity-modulated radiation therapy for T4 nasopharyngeal carcinoma
MX2023006793A (es) Tratamientos conjuntos para tratamiento de cancer her2.
Marina et al. Comparison of dose-escalated, image-guided radiotherapy vs. dose-escalated, high-dose-rate brachytherapy boost in a modern cohort of intermediate-risk prostate cancer patients
MX2023002805A (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos.
MX2022014180A (es) Metodos, terapias y usos para tratar cancer.
Yazar et al. Oncoplastic breast conserving surgery: aesthetic satisfaction and oncological outcomes
MX2021010228A (es) Administracion de inhibidores de pd-1 para el tratamiento de cancer de piel.
Hayakawa et al. The Effect of Overall Treatment Time of Radiation Therapy on Local Control of T1‐Stage Squamous Call Carcinoma of the Glottis
MX2022014133A (es) Tratamiento para cancer de mama usando tratamientos conjuntos que comprenden gdc-9545 y un inhibidor de cdk4/6.
AU2021334165A8 (en) Method of treatment of patients having reduced sensitivity to a BCL-2 inhibitor
Pellizzon Evidence and clinical outcomes of adult soft tissue sarcomas of the extremities treated with adjuvant high-dose-rate brachytherapy–a literature review
Morton The best method for dose escalation: Prostate brachytherapy
Guttmann et al. Comparison of acute toxicities between contemporary forward‐planned 3D conformal radiotherapy and inverse‐planned intensity‐modulated radiotherapy for whole breast radiation
Abtahi et al. High dose rate 192Ir versus high dose rate 60Co brachytherapy: an overview of systematic reviews of clinical responses of gynecological cancers from 1984 to 2020
Sumitomo et al. Efficacy of short-term androgen deprivation with high-intensity focused ultrasound in the treatment of prostate cancer in Japan
Senn et al. Adjuvant chemoimmunotherapy with LMF+ BCG in node-negative and node-positive breast cancer patients: 10 year results
MX2023003034A (es) Metodos, terapias y usos para tratar el cancer.
Zhang et al. Survey on the use of radiotherapy to treat early breast cancer following breast-conserving surgery in China
Jensen et al. Dose escalated simultaneous integrated boost of gross nodal disease in gynecologic cancers: a multi-institutional retrospective analysis and review of the literature
Hoskin et al. Single–dose high-dose-rate brachytherapy versus two and three fractions for locally advanced prostate cancer